You picked a fertility-sparing path for a reason: you want to feel like yourself and keep the option of kids on your own timeline. That's a smart instinct — and it comes with a detail most people skip: in men, estradiol is a major driver of bone strength, and hormone strategies can quietly change it.
The short version
Enclomiphene is a selective estrogen receptor modulator (SERM). In simple terms, it blocks estrogen signaling at the pituitary, which prompts the body to release more of its own signaling hormones (LH and FSH). That, in turn, can raise the testes' own testosterone production — and unlike injected testosterone, it keeps the testicular signaling axis running, which is why it's often discussed in fertility-minded contexts [1][2].
But here's the nuance that rewards a careful founder: some of the testosterone your body makes gets converted into estradiol (via the aromatase enzyme), and in men, estradiol is not a bystander. It's one of the main hormones your skeleton depends on. Push estrogen signaling around without watching the downstream markers, and "protecting fertility" can, over years, come at a cost you can't see until a scan shows it.
This article is educational and not medical advice. Whether any medication is appropriate is a decision only an independent licensed provider can make with you.
Why estradiol runs the skeleton in men
For decades, testosterone got the credit for men's bones. The research turned that assumption on its head.
The landmark work came from studying men with rare genetic conditions — an inactivating mutation in the estrogen receptor, or a deficiency in aromatase (the enzyme that converts testosterone to estradiol). Despite normal or high testosterone, these men had unfused growth plates, low bone density, and ongoing bone turnover — and in the aromatase-deficient cases, giving estradiol improved their bone density [3]. That was the clue: estradiol, not testosterone alone, is the dominant sex-steroid regulator of the male skeleton.
A carefully designed clinical experiment sharpened the picture. In a study published in the *New England Journal of Medicine*, researchers used medication to suppress men's own hormone production, then added back testosterone at varying doses — with or without blocking aromatase. When estradiol was blocked, markers of bone breakdown rose even when testosterone was maintained, showing estradiol's specific role in restraining bone loss [4].
Mechanistically, estradiol helps keep the two halves of bone remodeling in balance: it restrains the osteoclasts that break bone down and supports the osteoblasts that build it up. Suppress estradiol too far and that balance can tilt toward net loss over time [3][4].
Source: [3] Khosla S, Monroe DG. Regulation of Bone Metabolism by Sex Steroids (Cold Spring Harb Perspect Med, PMC), [4] Finkelstein JS et al. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men (N Engl J Med)
Where a SERM fits — and the tradeoff to name honestly
Enclomiphene works upstream, on the brain-pituitary side of the axis. Because it doesn't directly aromatase-block, the estradiol conversation with a SERM is often about the *pattern* of your hormones, not a deliberate estrogen crackdown. Still, the reason bone belongs in this conversation is simple: any strategy that changes your testosterone and estradiol relationship deserves markers on both sides of the ledger, tracked over time [1][2].
That's also the honest counterpoint to the gym-shortcut approach. Gray-market cycles — and especially DIY "estrogen control" with aromatase inhibitors bought online — can drive estradiol far lower than the skeleton wants, with no labs to catch it. Low estradiol in men is associated with unfavorable bone markers; it isn't automatically "cleaner" to crush it [4][5]. The supervised, lab-backed version isn't slower for the sake of it — it's the version that watches the thing you can't feel.
The markers a provider tends to watch
No single number tells the story. A provider looking at the whole picture typically considers a combination:
- Total and free testosterone — the primary reason many people start this conversation. The clinical threshold commonly cited for further evaluation is a total testosterone below roughly 300 ng/dL on a morning, fasting draw, repeated for confirmation [6].
- Estradiol — usually measured with a sensitive assay in men, because standard assays are less reliable at male-range concentrations. This is the bone-relevant marker that gets overlooked [4][6].
- LH and FSH — the pituitary signals a SERM is designed to influence; they help distinguish where in the axis the issue sits [6].
- Bone context over time — depending on age, symptoms, and duration, a provider may discuss bone density testing (a DEXA scan) as the long-term picture, since bone changes are silent until measured [3].
The point of tracking estradiol isn't to chase a magic number — it's to make sure a fertility-first plan isn't quietly running your skeleton on empty.
ng/dL total testosterone · marker = ~300 ng/dL cutoff
What this means if you're building — and planning a family
If your energy falls off a cliff by mid-afternoon and a walk-in panel got a shrug, the answer isn't to guess louder. It's to get a complete picture — including the markers a rushed visit skips — interpreted by someone who treats your fertility timeline as a real constraint, not an afterthought.
The skeletal angle is the long-game reason this matters. You may not feel your bone density at 34. You'll be glad someone watched it when you're 54. A fertility-sparing choice and a bone-aware choice are not in conflict — they're the same disciplined decision, made with data.
Where Velri fits
Velri is a technology and coordination company — not a medical practice. We help you get organized: coordinating lab work, connecting you with an independent, licensed provider for an evaluation, and — only if that provider determines it's appropriate and writes a prescription — coordinating with a licensed pharmacy. A prescription is never guaranteed; that decision belongs solely to the independent provider.
Some hormone-related therapies discussed in longevity medicine are compounded. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
This article is educational and is not medical advice, diagnosis, or a recommendation to take any specific medication. Talk with a licensed provider about your individual situation.
